COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162 RNA-Based COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Pfizer. (2020). PF-07302048 (BNT162 RNA-Based COVID-19 vaccines) protocol C4591001. Summary: The document outlines the Phase 1/2/3 clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of BNT162 RNA-based COVID-19 vaccines, developed by Pfizer and BioNTech. The trial investigates two vaccine candidates: BNT162b1, encoding the receptor-binding domain (RBD), and BNT162b2, encoding the prefusion spike […]